Current Pharmaceutical Research (CPR)
Vol 1, Issue 3, July-September 2025
Journal Homepage: https://cpr.org.in/

# Clinical Aspects, Epidemiology, and Management of Hepatitis Viruses: A Comprehensive Review

*Shalini Rana, 1Vipin Kumar, 2Firoz Khan, 2Achla Sharma

*Assistant Professor, School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab, India, Email id-Shalinirana292@gmail.com

[1]Research Scholar, School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab, India, Email id-vipin952390@gmail.com

[2]Assistant Professor, School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab, India

**Keywords**

Hepatitis viruses, Hepatitis B, Hepatitis C, Epidemiology, Cirrhosis, Hepatocellular carcinoma, Chronic liver disease, Vaccination, Antiviral therapy, Global health

**Abstract**

Hepatitis viruses, including types A, B, C, D, and E, present significant global health challenges, with varying prevalence and clinical manifestations depending on geographical regions. These infections are associated with liver diseases, ranging from mild acute conditions to chronic complications like cirrhosis and hepatocellular carcinoma. Hepatitis B and C are particularly concerning due to their potential for long-term chronic infections that may result in severe liver damage. The pathogenesis of hepatitis viruses involves complex interactions between viral factors and the host's immune system, leading to liver injury. While vaccines are available for hepatitis A and B, and antiviral treatments have made progress, challenges remain in managing these infections globally, especially in low- and middle-income countries. This review discusses the epidemiology, clinical outcomes, diagnostic methods, and treatment options for hepatitis viruses, highlighting the need for improved public health strategies, early diagnosis, and effective antiviral therapies to mitigate the global burden of hepatitis infections.

***Corresponding Author:**
***Shalini Rana,** (Shalinirana292@gmail.com)

**Article Info**
Received: 22 May 2025, Received in revised form: 03 September 2025, Accepted: 18 September 2025, Available online: 10 October 2025

ISSN: 3049-2955/The authors © 2025, under exclusive license to the Sprout Publication
DOI: https://doi.org/10.63785/cpr.2025.1.3.323337

## 1. Introduction

Hepatitis viruses are an enormous clinical, social, and economic burden that often require multidisciplinary management, taking into account multiple human rights considerations. There are non-A to E hepatitis viruses, which are important in limited areas with unique distribution. The routinely used clinical virus taxonomy that includes DNA viruses, RNA viruses, and retroviruses is not equally useful in all clinical situations. An anatomical approach to clinical virus classification includes an understanding of metagenomes, providing a new taxonomy [1], [2]. All of our defenses against viral infection are part of the ancient innate host defense system, so the response of the hepatitis viruses we have carried with us through evolution is vital to our understanding of medicine as well as to global medicine as a whole. The burden of viral hepatitis on populations and healthcare systems is also likely to rise, making the already large burden even larger. Multiple oral antiviral treatments with a high barrier to resistance are now licensed for chronic hepatitis B, chronic A, chronic C, and chronic E. Effective disease prevention and control strategies require a deep understanding of the viruses [3].

Hepatitis viruses are classified as hepatitis A, B, C, D, and E. These viruses are dissimilar in some aspects from each other. They have different routes of transmission, and while hepatitis A and E are mainly transmitted by the fecal-oral route, hepatitis B, C, and D are transmitted by parenteral, perinatal, and sexual contact. Moreover, they have unrelated overall structural and genome organization and belong to different taxonomic groups within the family [4]. These epidemiological and clinical differences justify the different approaches to their prevention. As a

common feature, HBV, HCV, HDV, and HEV may establish persistent infections in some individuals. HBV is the most relevant in this sense, with up to 90% of newborns who became infected at birth developing a long-term infection [5], [6].

Patients with Hepatitis A, Hepatitis E, and sometimes Hepatitis B present with a self-limiting minor hepatic injury, from which they completely recover in a few weeks and months. Hepatitis C and Hepatitis D might be more severe in some individuals, progressing to chronic severe liver diseases, such as cirrhosis and HCC. All the hepatitis viruses are present worldwide but show different extents of distribution [7]. Hepatitis A causes outbreaks and epidemics, and it is spread especially where there are poor sanitary conditions. Hepatitis B, Hepatitis C, and Hepatitis D infections are considered endemic in Asia and Africa, whereas they are rare in Australia and in Western countries, with a prevalence of less than 2%. HBsAg carriers may show hepatic and extrahepatic diseases, but the presence of co-infections may negatively contribute to damage caused by multi-infections. Resolved cases have no symptoms and are accidentally diagnosed by detection of antibodies to HBV proteins or HCV RNA. Detection of HBsAg in subjects may occur in an early phase after infection shown in table 1 [8], [9].

**Table 1: Different types of Hepatitis virus types, their characteristics and clinical manifestations.**

| S. No. | Hepatitis Virus Type | Transmission Route | Common Characteristics | Chronic Infection Risk | Global Prevalence | Vaccine Availability | Key Clinical Manifestation | References |
|---|---|---|---|---|---|---|---|---|
| | Hepatitis A (HAV) | Fecal-oral route (contaminated food or water) | RNA virus, self-limiting, usually mild hepatic injury | Low | Common in areas with poor sanitation | Yes | Acute Hepatitis, Jaundice, Fatigue | [10], [11] |
| | Hepatitis B (HBV) | Parenteral (blood), perinatal, sexual contact | DNA virus, can cause chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC) | High (especially in newborns) | Endemic in Asia, Africa, parts of South America | Yes | Acute and Chronic Hepatitis, Cirrhosis, HCC | [12] |
| | Hepatitis C (HCV) | Parenteral (blood), sexual contact | RNA virus, chronic infections often lead to cirrhosis and HCC | High | Endemic in Southeast Asia, Africa, parts of Europe | No | Chronic Hepatitis, Cirrhosis, HCC | [13] |
| | Hepatitis D (HDV) | Parenteral (blood), requires HBV for co-infection | Defective RNA virus, only occurs in those infected with HBV | High (co-infection with HBV increases risk) | Found in regions with high HBV prevalence (e.g., Mediterranean, Southeast Asia) | No | Severe Hepatitis, Rapid Progression to Cirrhosis | [14], [15] |
| | Hepatitis E (HEV) | Fecal-oral route (contaminated food or water) | RNA virus, mostly self-limiting, can cause acute liver failure in pregnant women | Low | Common in Asia, Africa, and parts of Central America | No | Acute Hepatitis, Jaundice, Fatigue | [16] |
| | Hepatitis G (HGV) | Parenteral (blood), sexual contact | RNA virus, often asymptomatic, can be associated with HCV or | Low | Worldwide, less studied | No | Often asymptomatic, mild liver inflammation | [17], [18] |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | | | HIV co-infection | | | | | |

## 2. Epidemiology and Global Burden of Hepatitis Viruses

Hepatitis viruses. The worldwide burden of viral hepatitis is immense, with a variable incidence rate in different regions of the world. The prevalence of hepatitis also varies from one country to another, depending on socioeconomic status, access to healthcare facilities, and standard of living. The incidence of hepatitis is higher in low- to middle-income countries, and the prevalence rate in men is higher than in women. Poor knowledge of prevalence may lead to severe acute hepatitis and acute on chronic liver failure with poor prognosis [19], [20].

Globally, hepatitis epidemiology has been changing over the years. Screening affects the epidemiology of hepatitis, leading to an increase in the reported global burden of hepatitis viruses. Strategies for limiting or eradicating viral hepatitis include early diagnosis, appropriate treatment, enhancement of health infrastructure, immunization of high-risk individuals, implementation of blood donation screening procedures, standardizing the commonly practiced interventions, creating awareness of the disease, and programs to control and manage infections and transmission, and allocation of resources devoted to healthcare so that hepatitis is less of a healthcare priority [21]. The application and compliance with effective antiviral treatments can lead to a decline in the prevalence of hepatitis viruses. In the last few years, an increase in the diagnostic rate was seen, and a survey result indicated that viral hepatitis B and C had declined by 30% in the year 2016, and with the elimination of hepatitis C, even a decline in cirrhosis-related deaths is predicted in the United States until 2042 [22]. The prevalence of seropositive hepatitis carriers varies among countries and geographical areas. Clinical experience and governmental control programs are essential for understanding and preventing the rapid spread and infection of other populations [23]. The Sub-Saharan region, South America, Eastern Mediterranean, South-East Asia, and Western Pacific areas have a higher incidence of hepatitis. The prevalence of infection is commonly observed in risky populations, including war-affected individuals, blood transfusion recipients, and healthcare recruits. Slum areas, poor economic status, and inadequate public health facilities assist in the progression of hepatitis virus infection. Confiscation of such areas is hard because of an inadequate financial deal [24], [25]. Awareness campaigns and government-approved programs are necessary for the immediate stability of hepatitis-infected regions. Hepatitis has a variable incidence and prevalence; therefore, there is a need for surveillance in these regions. Up to the timeframe of 2019, an increased global incidence has been observed by analyzing surveillance recordings. Favored national policies require an assessment of the applications and overall progress of a vaccination program as well as that of intervention activities and healthcare norms [26]. Control strategies based on surveillance and research meet requirements for applied disease or system-based short-term population-based targets and conditions. Environmental studies fulfill communal and societal programs. Hepatitis does not relate to any particular race, lifestyle, locality, or economic status but is differently observed in various groups. Synergy across an extended network of authorities is warranted to treat and eradicate hepatitis from the public. Vaccination is used as an immunity booster in the affected zones to develop resistance and resilience against the hepatitis virus shown in figure 1 [27], [28].




**Figure 1: Number of hepatitis B notifications and notification rate per 100,000 population, 1997-2024. (Data source: CIDR).**

Global Distribution of HCV and HBV Prevalence Geographical variations in the endemicity pattern of HBV and HCV account for different prevalence levels across different countries. Indeed, facilitated by low or missing healthcare accessibility, unsafe cultural practices such as tattooing, multiple needle use, crowded conditions in healthcare settings, and complicated cultural habits, HBV and HCV also show hot areas with prevalence rates greater than 15% or even higher. HBV, in particular, is present in only four countries with prevalence rates greater than 8%, such as Benin, Burkina Faso, Nigeria, and Tanzania [29]. On the other hand, HBV endemically coexists and overlaps with nations with intermediate prevalence (greater than 2% and less than 7%) and low prevalence (less than 2%) [30]. Some geographical disparities are likely due to the implementation of early control strategies and widespread vaccination campaigns. In high-income countries, viral hepatitis rates are low, with estimated HCV and HBV prevalence rates below 1.5%, and the gentrification of these countries could affect a real decrease in the incidence and spread of the viruses [31], [32].

Incidence Liver disease due to an HBV and/or HCV infection is cumulative over time and may result from both acute and chronic infections. So far, according to records, the acute cases reported in the European region, the Southeast Asian region, and the Western Pacific region have steadily declined since 2015. Projections of decline in incidence, adjusted to population age, varied between areas, showing that HBV and HCV incidence cases are estimated to shrink from -1.8% to -2.5% per year [33]. In particular, HBV incidence is expected to decline by -1% in low-HBV prevalence regions and by -2.5% in high-HBV prevalence areas. Instead, HCV incidence is expected to fall to higher rates of -2.5%, from -1.8% in the areas with more precarious liver health services. A decrease in mortality is expected through 2045, although this may slow down for non-Hodgkin lymphoma and liver cancer as patients with cirrhosis get older. In the latter case, there may be a decrease in liver cancer rates, but the onset of the decline is uncertain [34], [35].

## 3. Pathogenesis and Mechanisms of Hepatitis Virus Infection

Hepatitis virus infection begins with the attachment of viral particles to molecules on the surface of susceptible host liver cells and is followed by viral entry. Following viral entry, the genomes of hepatitis viruses are liberated and their encoded viral proteins generated, using host cell machinery [36]. These viral components interact with a multitude of cellular pathways and molecular components to support the process of viral replication and packaging of new progeny virions. At the same time, these molecular and protein components of hepatitis viruses also alter the antiviral immune responses of the underlying host liver and immune cells that are attempting to clear the hepatitis virus from the liver [37], [38]. The molecular footprints of these virus-mediated changes in host cell processes, in conjunction with limiting hepatitis viral replication, alter the behavior of other cell types involved in responses to liver injury and thus contribute to the development of progressive liver damage in those infected with hepatitis viruses. As a corollary, these cellular reactions, control of viral levels, and the intensity and nature of antigen-specific immune responses are heavily influenced by coinfections with other organisms, host viruses, and liver-directed immune responses that affect disease pathogenesis and therapeutic clinical care management decisions [39].

Liver biopsy specimens from individuals infected with hepatitis viruses supply evidence of the activation of genes involved in defense against viral infection, as well as the cytotoxic immune cell types that assist in viral clearance from the liver [40]. The extent of these histological changes depends upon both virus type and host genome and is instrumental in diverging outcomes of disease progression. Individuals may have fulminant liver failure, rapid onset leading to death from complications of supportive treatment for hepatitis, acute-onset chronic liver injury, manifesting in chronic hepatitis, cirrhosis, and/or liver cancer, or newly apparent cirrhosis [41]. As mentioned, the level of liver damage is dictated in part by virus-host interactions in addition to pro-inflammatory cytokines generated in the immune response to the hepatitis virus infection in the liver itself. Some groups are at a higher risk of developing more intense liver injury, characterized by high transaminase levels: elderly individuals, those with previous or active alcohol use, those with chronic underlying liver disease, and pregnant women [42], [43]. Treatment of these conditions would be approached with an aim to alter the expected clinical outcomes by both improving viral clearance as well as modulating the intensity and nature of the ongoing immune response to these hepatitis viruses. The multidisciplinary research program employed to unravel these complex molecular processes involved in hepatitis infection allows us to better define therapeutic targets for the development of new therapies against viral infection and liver disease or the improvement of the current recommendations for patient management and treatment shown in figure 2 [44], [45].




**Figure 2:** The image illustrates the life cycle of the Hepatitis B virus (HBV) inside a host cell; It begins with the virus binding to a receptor on the cell surface (1), followed by fusion and endocytosis (2). The virus is then uncoated and imported into the nucleus (3), where host proteins repair gaps in the viral DNA (4). Transcription occurs, producing viral cccDNA (5), and the virus's core structure is synthesized in the endoplasmic reticulum (6). Assembly of new viral particles takes place (7), followed by budding (8) and release of new viruses (9) from the host cell.

Viruses gain entry to liver cells known as hepatocytes through viral glycoproteins or interactions with host cell receptors using viral capsid proteins. The viral entry/replication process is critical for the understanding of viral infection and for the development of antiviral strategies because it defines how the virus maintains infection within the liver. Hepatitis viruses apparently replicate within the cytoplasmic compartments of infected hepatocytes in a process that is under the control of host cellular factors [46].

HBV replicates via an unusual RNA-intermediate life cycle involving intra-nuclear cccDNA, the partially double-stranded DNA intermediate, and the relaxed circular DNA form. HCV RNA replication and genome translation occur on the surface of the endoplasmic reticulum, and infectious particles develop from lipid-rich ER compartments before budding from the ER membrane into the cytoplasm of the infected cell. In contrast, DENV and YFV cooperatively replicate in close association with double membrane vesicles that derive from the rough ER, while the core proteins of HCV may alter lysosomal trafficking [47], [48]. A fundamental theme of these divergent replication cycles is that viral infection can increase biogenesis of metabolic membranes and harness peroxisomal and/or mitochondrial networks for replication organelle formation. Secreted viral particles are non-cytopathic, and during negotiations with many hosts cellular factors, viral infection may potentially debilitate the infected cell in preparation for glucocorticosome-mediated immunosuppressive activation. A more detailed understanding of the viral life cycle in terms of hepatitis virology is expected to yield future therapeutic strategies [49].

## 4. Clinical Manifestations of Hepatitis Infections

Many hepatitis virus infections are often subclinical and do not require intervention. However, when the affected patients are symptomatic or the infection becomes chronic, problems may arise. Hepatitis viruses mainly act on hepatocytes, but they have extrahepatic involvement as well. The varying clinical manifestations of hepatitis virus infections include asymptomatic cases with chronic carrier elevation of viral load [50]. Acute hepatitis, when recognized, often resolves during the convalescent stage, but without intervention, it can evolve into a chronic infection or progress to fulminant hepatitis. Subacute illnesses such as acute severe hepatitis with symptoms and chronic hepatitis with inflammation and liver cell damage coexisting with fibrosis are known as fibrotic lesions. Cirrhosis occurs when fibrosis progresses and increases hepatic vascular resistance, leading to portal hypertension. Compensated cirrhosis generally does not cause any symptoms or signs, except for spider angiomata, but as time goes on, new capillary vessels emerge [51], [52].

Several clinical forms that affect only viral load levels are also commonly found across the extras and genotypes. Host factors such as age, gender, genetic predisposing factors, nutrition, comorbid illnesses, coinfection, and HIV viral load are the main

determinants of the clinical hallmarks of hepatitis virus infection. In addition, clinical signs and symptoms are varied and nonspecifically associated with hepatitis virus infections. Therefore, the identification of hepatitis virus infections is the cornerstone for assessing knowledge of their clinical manifestations, with an emphasis on early diagnosis and intervention. This course will look at the clinical manifestations of hepatitis viruses from the cradle of the womb to the grave of the gastroscope [53].

Hepatitis virus brings an enormous spectrum of clinical consequences. We have to distinguish between acute hepatitis and chronic hepatitis. An episode of acute hepatitis has a sudden onset, and remission of symptoms usually occurs within six weeks. In any case, these patients present jaundice, dark urine, liver enlargement with right upper abdominal tenderness, and systemic manifestations such as anorexia, malaise, nausea, and vomiting [54]. On the other hand, chronic hepatitis may progress slowly, being insidious and frequently asymptomatic for several years. The human immune response is responsible for the chronicity of hepatitis viruses, which develops in 5–90% of individuals after acute infection. Consequently, there is recurrent inflammation that causes progressive damage to the liver, ultimately leading to liver cirrhosis and/or hepatocellular carcinoma, which are the most serious complications of chronic hepatitis [55], [56].

The risk that acute hepatitis becomes chronic infection is greatest in childhood, ranging from 90% in the first year of life to less than 5% in adult subjects. Since chronic infection is generally asymptomatic, eventually the diagnosis of chronic hepatitis can be established based on detecting an exception between its usual laboratory tests. Therefore, most studies report chronic hepatitis as the number of patients with HBsAg detected for over six months [57]. Acute infection generally does not require treatment and is cured. Nevertheless, antiviral therapy may be considered in the acute phase to prevent the transition to chronicity in specific situations. An improved understanding of the molecular mechanisms that drive the presentation to one or the other outcomes is crucial for effective strategies to control and possibly prevent viral hepatitis shown in figure 3 [58].




**Figure 3: Hepatitis virus infection in Acute Hepatitis & Chronic Hepatitis.**

**5. Diagnostic Approaches for Hepatitis Viruses**

Various methodologies can be used to diagnose hepatitis virus infection, whether the infection is acute or chronic. Two diagnostic approaches have classically been used for the initial diagnosis of hepatitis virus infection: the first for the detection of starting events of host immunological response, to identify exposure to the virus; the second to confirm or exclude the presence of viruses and, eventually, to identify their genotype [59]. Serologic tests use not only venous blood samples but also other types of biological materials, such as hair, to detect antibodies against specific viruses, both those against the virus particle and those which are capable of inhibiting viral replication. They usually provide an indirect view of the body's response to a predominantly self-limited infectious process and, therefore, have some limitations [60].

The existence of a large window period, i.e., the period during which screening and confirmatory tests will be negative despite the actual presence of the virus in the blood, is the principal reason they are supplemented with more confirmatory direct tests that primarily detect the presence of the virus's genetic material. Molecular techniques have to be considered the gold standard approach for the diagnosis of single infections. Several diagnostic kits using blood, plasma, or serum for the diagnosis of viral hepatitis are on the market [61], [62]. Just like all diagnostic methods, these tests have limitations because they can lead to substantial rates of false-negative results, mainly due to mutant viruses that are less efficiently detected by

the probes and/or primer-based systems, and false-positive results, especially when used for screening purposes. Yet, early diagnosis is the prerequisite for designing effective and individualized treatment plans. Accordingly, some scientific societies recommend the routine screening of populations, such as those with comorbidities or those taking immunosuppressants, at an increased risk of infection due to the viral prevalence in their residence. Numerous advances in the diagnostic approach have taken place recently, following the rapid development of molecular approaches that have led not only to the identification of HBV and HCV but also to the identification of many other hepatitis viruses, fueling the research and the progress of antiviral management [63].

Infection with hepatitis A, B, C, D, and E can be diagnosed using serologic tests. The prognosis of the infection and chronic liver disease varies between the hepatitis viruses, and determination of the causative agent has important implications for clinical management and for the prevention of transmission in the community. Commercial immunoassays are widely used in clinical laboratories to detect hepatitis viral antigens or antibodies [64]. However, in certain situations, molecular techniques may be the best choice for the detection of active infection and for monitoring antiviral therapy. Antibodies directed against hepatitis viruses are detected in blood samples by serologic assays. Detection of antibodies to hepatitis viral antigens implies that a person has been exposed to the virus, has responded to the virus, and is either recovered from the infection or is a carrier of HCV [65].

Molecular techniques are of two types: amplification of target sequences through DNA or RNA and non-amplification techniques for direct detection. Target amplification techniques allow efficient and rapid detection of viral nucleic acids with rapid or hybridization detection systems. Detection of hepatitis viral antigens or antibodies by serologic assays does not necessarily mean that the individual is currently infected or is suffering from the disease. The presence of viral nucleic acid is a more reliable indicator of an active infection [66]. Molecular techniques provide a rapid diagnosis of current or early resolved infections. The ability of serologic techniques to detect specific antibodies and antigens is used to develop related diagnostic tests with various advantages and disadvantages. In general, serological tests are easy, quick, and sufficiently cheap. However, particularly for circulating antibodies which have long-term effects and can persist for an extended period. Thus, emerging diagnostic techniques in addition to the current commercial diagnostic kits may prove highly useful in hepatitis infection diagnosis [67]

.

## 6. Management and Treatment Strategies for Hepatitis Infections

Current management of viral hepatitis A, E, and other related forms is mostly supportive in nature. Guidelines suggest recommendations spanning all grades of disease severity, leading to a symptomatic approach for those who experience symptoms. Although available treatment strategies for these forms are limited, they ultimately result in improved patient outcomes and reduced severity and duration of the disease. This is contrary to hepatitis B and C, which have developed in several people over the years. Over time, many viral or host targets have been exploited in the form of antiviral therapies. These strategies result in dramatic improvements in HCV and HBV eradication but come with a diverse range of adverse events or limited availability due to higher costs [68].

Various studies and reviews have evaluated patient characteristics such as the course of infection, age, associated comorbidities, viral genotypes or subtypes, risk factors such as injection drug use, and, more importantly, patient education, adherence, and iTx as important factors to consider before deciding on the treatment or management plan. The management plan for the control of viral hepatitis is incomplete without addressing chronic viral hepatitis complications, and those of HBV or HD can potentially improve with increased vaccination coverage [69]. Another reason treatment plans are important is the concept of combination therapy, and the balance between treatment toxicities or adverse events and expecting compliance, willingness to take medications and follow-ups, adherence, and the likelihood of a response to clear or inhibit the multiplication of viruses. Moreover, viral etiologies vary and influence the choice of management plan, if and when to treat, when to use antivirals, which antiviral medications to use, and at what point to decide the best way to reassess and reinitiate treatment. All of these are points of individualized patient management based on response, viral factors, and patient factors [70].

Since the replication cycle of HBV and HCV overlaps, several HBV NAs and Peg-IFN, in addition to DAAs, have been developed to treat chronic HBV and/or HCV mono-infections. Among them, LBV, TDF, and ETV are nucleotide-based analogs, whereas IFNs, LAM, TBV, TDF, and ETV are nucleoside-based analogs. PEG-IFN plays an important role in immune modulation and DAAs inhibit a wide range of viral proteins and differ in their mechanisms of action. In outcomes, DAAs used in triple-regimen therapies in HCV mono-infected patients have proven very effective, even in the retreatment of HCV-infected hemodialysis patients or HIV co-infected patients [71].

Vaccination programs for the prevention of HAV and HBV were introduced in some countries in 1992, everywhere by 1995, and vaccination for HCV was held in Canada in 1997 and in the United States in 1998. Despite several global public health challenges related to the vaccination of a huge number of individuals, far more successes have been achieved with the current vaccination programs [72]. Each year, vaccination prevents over 90,000 deaths due to HBV and 3,000 deaths related to HAV worldwide. HBIG plus inoculations is 95% effective at preventing HCV transmission in newborns from an HBV positive mother, and 94% to 98% of post-exposure HBV infections can be prevented when the first dose of the HB vaccine and HBIG is given within 7 days of birth. If the exposure is prior to vaccination, it is better to give HBIG alone until the post-exposure vaccination.

Thus, HBIG is not a functional reinforcement vaccine in post-exposure, but it provides pooled hepatitis B immunologic globulin [73].

## 7. Complications and Long-Term Sequelae of Hepatitis Infections

The prolonged course of progression of liver disease can be accompanied by unwanted events and long-term outcomes. The severity and frequency of these unwarranted events demonstrate how pivotal inflammation is in the pathogenesis of hepatic diseases. For this reason, complications and, particularly, sequelae are inexorably linked to hepatic inflammation and can cause severe and sometimes life-threatening conditions in untreated carriers of the viruses. Complications of liver diseases are mainly represented by disturbances in hepatic function and portal hypertension syndrome, often in combination [74].

Hepatitis infections are a major cause of cirrhosis, liver failure, and primary liver cancer: cirrhotic patients supplying more than 40% of total liver cancer cases worldwide. Each patient with HBV and HCV has his or her own pattern of progression of liver, but liver inflammation is the central event leading to liver damage. The HCV genome replicated during chronic infection is related to the subsequent rate of cirrhosis [75]. The basic mechanisms promoting liver damage and many covariables related to the risk of progression of liver disease and influencing the individual pattern of liver disease progression have been extensively described. Indeed, co-infections, mainly HBV and HCV and human immunodeficiency virus and hepatitis viruses, are frequent scenarios that can lead to premature severe sequelae. Lifestyle and dietary habits can exert a significant positive or negative risk to progression of liver disease [76].

Liver cirrhosis and hepatocellular carcinoma (HCC) are two of the most severe complications of hepatitis infections, especially in the case of chronic hepatitis.

Liver cirrhosis is the result of the excess deposition of collagen fibers, resulting in distortion of the liver architecture. The physiological consequences of this process include increased intrahepatic vascular compression, leading to an increase in portal pressure and the associated arterial hypotension. Chronic inflammation is the pivotal physiological mechanism of the disease, leading to progression to fibrosis and later cirrhosis [77].

Multiple cell types, such as resident Kupffer cells, liver sinusoidal endothelial cells, hepatic stellate cells, and infiltrating immune cells, have been found to be involved in the fibrotic process. HCC is a leading cause of cancer death, and both fibrosis and cirrhosis are the most significant factors that accelerate the development of HCC. The main tenet in preventing and treating HCC, as a severe complication of hepatitis, is to minimize all the risk factors or promoting factors [78]. A quarter of HCC cases arise from hepatitis infections, especially from HBV infection, and a small percentage from hepatitis C infection. HBV and HCV with advanced fibrosis are believed to have a higher probability of developing HCC. The majority of HCC diagnoses are based on the incidental diagnosis of liver cirrhosis patients. Hence, this may suggest that the liver blood tests may have been deranged for a long duration without a formal diagnosis [79]. The only direct curative therapy that may alter the natural course of HCC is liver transplantation. A multidisciplinary approach is encouraged in patient care, as a combination of active monitoring, interventional therapy, systemic therapeutics, palliative care, and social support is needed in late liver disease, irrespective of etiology [80]

.

## 8. Special Populations and Hepatitis Virus Infections

Chronic viral hepatitis is a major cause of liver mortality worldwide, but liver-related morbidity and mortality can also occur at a younger age in some populations. In this section, it is explained that, due in part to their birth cohort or behavior, some individuals develop evidence of liver disease earlier in life. The ability to provide patients with evidence of life-stage fibrosis can help increase patient adherence to medical advice and potentially decrease the frequency of those lost to follow-up processes in the absence of disease-specific symptoms. The discussion follows up by addressing not only the prevalence of hepatitis virus infection in pregnant women and newborns, but also its impact on the health of both mother and child [81].

Special populations. These sections describe some of the possible consequences that the timing of viral hepatitis infection relative to birth, pregnancy, or certain behaviors has on disease progression and possible management. Topics include: the growing problem of hepatitis delta; the consequences of hepatitis B and delta infection in pregnancy and risk to newborns; pediatric and adolescent hepatitis; accelerated viral hepatitis C progression and fibrosis in HIV co-infection; injecting and non-injecting drug use as a risk for hepatitis infection; breast milk and breastfeeding [82]. Populations affected by HBV and HCV infections are often studied only infrequently in clinical science literature; these include adolescents in whom behavior may play an outsized role in outcomes, much as in certain adult populations. Further studies on these and related populations can inform public health initiatives, and paying attention to sociocultural and other influences on health itself can help move the field of liver and viral hepatitis from a global to an equitable realm [83].

### 8.1. Pediatric Hepatitis Infections

The care of children with clinical infections is an emerging field. In the field of viral hepatitis, it carries particular challenges. The clinical presentation of a hepatitis virus infection is much more heterogeneous in children than in adults. The traditionally appreciated means by which to ascertain a diagnosis are often unsatisfactory in children [84]. This problem is exacerbated by the impracticability of an essential diagnostic test. In the future, efficacious antiviral

therapies will clearly have to be developed by a process in which pediatric patients figure as more than afterthoughts. This chapter describes infections with these viral pathogens in children. The situations encountered are generally quite distinct from those that present in adulthood. We describe the challenges and bring as many human faces as we can to the subject, with the hope that children living in challenging settings receive the care that they need [85].

The likelihood of a child with acute viral hepatitis progressing to chronic carriage ranges from approximately 80% in hepatitis B with a perinatally acquired infection to around 20% with a perinatal HCV infection. The complications of long-term carriage with hepatitis viruses can be life- and organ-threatening, and the impairments in the anthropometric and cognitive development of children are likely major contributors to capital aggregation, as well as general societal inefficiency in many parts of the developing world [86]. The first wave of successes, finally putting measures in place to stop people dying inappropriately, as their contemporaries throughout the world now mostly do, came from mandatory immunization. The success in the real-world treatment of viral pediatric hepatitis is now awaited with comparable intensity. The achievements will, of necessity, be developed with a child-friendly focus [87].

## 9. Prevention and Control Measures for Hepatitis Viruses

Vaccination campaigns are great tools for limiting the spread of an infectious disease and for the eradication of the causative virus. Because of this, a number of hepatitis vaccination initiatives have been developed by numerous stakeholder entities. Vaccination policies based on these initiatives, which recommend the inclusion of universal hepatitis A vaccination as part of routine childhood vaccinations, have shown the potential to drastically reduce the worldwide prevalence of the disease. As a result of these interventions, the prevention of hepatitis B and its long-term sequel, hepatocellular carcinoma, is estimated at an impressive over 70% in the vaccine coverage areas of the world. These particular successes underscore the effects that a public health initiative can have [88].

One of the best prevention strategies that can be implemented is ensuring that the public has access to information. As many hepatitis viruses are communicable, it is important that communities are adequately educated about the ease of virus transmission. Highlighting prevention strategies and safety measures can help those in high-risk groups avoid infection. If an individual is at risk or engaging in high-risk activities, there are a variety of interventions and strategies that are commonly used with the intent of reducing the risk of acquiring the infection, including but not limited to safe sex practices, needle exchange programs, needle safety, and sterilization [89]. Regular screening and referral of clinical care can be used in clinical settings to prevent disease progression if applied early. Healthcare organizations can also reduce the transmission of hepatitis with the use of standard precautions, and at-risk workers should make use of a hepatitis B vaccination to prevent infection. Management of hepatitis patient symptoms with antiretroviral therapy can also help to eliminate the spread of the virus. At the end of the day, prevention is the most effective way to stop hepatitis. Thus, efforts should be made to ensure that those individuals who work with the public are educated about the signs and symptoms of various forms of hepatitis [90]. These professionals are considered the front line of defense in that they will be the first to be notified if an outbreak were to take place. Preventive action is also important with vaccines. To date, clinical attention to vaccine research has primarily been focused on: (a) finding an immunization model that protects against all viruses in a single vaccination, (b) developing new candidate vaccines for previously untreated viruses, and for some, new compositions of licensed vaccines. Regular screening and care referral can prevent the disease from progressing if applied early in a clinical setting [91]. Collaboration between healthcare providers and public health organizations is essential, as the healthcare provider usually has the most face-to-face contact with the potential patient and is in the best position to provide education about infection prevention. Utilization of data collection and analysis will provide a clear roadmap on how to target prevention and control strategies. By implementing these evidence-based strategies, we can greatly reduce the global burden of hepatitis shown in table 2 [92].

**Table 2:** Hepatitis Prevention and Control Measures.

| S. No. | Prevention and Control Measures | Description | References |
|---|---|---|---|
| | Vaccination Campaigns | Vaccination is a key tool to reduce the spread and eradicate the hepatitis viruses. Universal hepatitis A vaccination can drastically reduce global prevalence. Hepatitis B vaccination prevents long-term sequelae, such as hepatocellular carcinoma, in over 70% of vaccinated areas. | [93] |
| | Public Education | Educating the public on virus transmission and prevention strategies is essential. High-risk groups should be informed about transmission routes and preventive measures. | [94] |

| | | | |
|---|---|---|---|
| | Prevention Strategies and Interventions | Key strategies include safe sex practices, needle exchange programs, needle safety, and sterilization. Regular screening and timely clinical referrals are important to prevent disease progression. | [95] |
| | Healthcare Provider Engagement | Healthcare organizations can prevent transmission by adhering to standard precautions. Healthcare professionals should be educated on hepatitis symptoms and be at the forefront of detecting outbreaks. | [96] |
| | Antiviral Therapy | Management of hepatitis symptoms with antiviral therapy can significantly reduce virus transmission. | [97] |
| | Preventive Action | Vaccines play a crucial role in preventing hepatitis infection. Research is ongoing to develop vaccines that protect against multiple hepatitis viruses in a single shot. | [98] |
| | Collaboration Between Healthcare Providers and Public Health Organizations | Collaboration ensures timely intervention, spreading knowledge about infection prevention, and utilizing data collection and analysis for evidence-based strategies to combat hepatitis globally. | [99] |

Strategies to ensure continued control over hepatitis virus infections include public health programs to educate the public in preventive measures. Comprehensive education programs are needed to inform patients of their potential risk of infection with one or more hepatitis viruses and must be developed and administered by the national, state, or territory health departments in conjunction with organizations [100]. Methods to correct misperceptions may include the development of basic educational programs to increase the knowledge of the local community and improve their attitudes towards individuals with hepatitis. Media campaigns targeting high- and low-risk groups for hepatitis B have also been developed and include a hepatitis B vaccination strategy for targeted school children, a youth hepatitis B radio campaign involving multicultural stations, and educational workshops targeting daycare providers [101].

School- and community-based hepatitis information programs have been based on the premise that people can reduce the risk of hepatitis in their communities if provided with basic information, limited quantifiable data on aetiological transmission, safe practices, and self-help information on behavior change strategies for those who wish to reduce the risk of small bowel disease [102]. The role of the school was seen as instrumental in the transference of skills and knowledge attained at a youth blood-borne virus conference to individual schools, members of the health team at the schools, peers in the school community, family members of the students, and into the wider community where their schools were situated. The study found that there is a need for a change in the sexual health education provision to create informed and skilled individuals [103]. There is a great need for sexual health messages that are appealing to young people, to change people's attitudes, to break down barriers and dispel myths and fears, to foster an understanding, and provide the opportunity for constructive actions and allow young people the right to make informed choices and decisions. Evaluation of the project demonstrated that changes did occur. The research data showed that a shift was detected in attitudes towards social issues, beliefs, and changing perceptions of risk. This shift also cleared the way for many communities to introduce personal development education into the curriculum. Monitoring and evaluating the impact of such education programs and tailoring or adjusting information in response to the findings would assist in strengthening the consumer's ability to make informed and wise decisions about their health [104].

## 10. Future Perspectives and Research Directions in Hepatitis Virus Studies

The successive years should provide a wealth of information and significant breakthroughs. The most urgent need is for increased access to patients for clinical studies. Different populations need to be addressed and new treatment regimens to be tested throughout the spectrum of the different disease stages. Out-of-the-box ideas may significantly change the way we approach antivirals in the future, and the similarities in the viral lifecycle may open new therapeutic avenues. The establishment of novel therapies will help to close remaining gaps from treatment. Drug repurposing and novel combination therapies will need to be explored. At the end of the day, the current treatment regimen is still not without significant side effects, and many patients are still waiting for the drug that will eventually cure their condition once and for all [105].

In addition, this period calls for definitional studies that are needed in understanding the most impactful safety, PK/PD, and cost-effectiveness endpoints to ultimately elucidate future treatments related to these. Research in current gaps includes studies in immune tolerance and regulatory implications, the significance of HBsAg titre changes during treatment, and the utility of the cccDNA and HBx. In the immediate future, transcriptomic, proteomics, and epigenetic studies will define future novel therapeutic targets and understanding of mechanisms of immune escape from HBeAg seroconversion and how this can be a valuable approach for HBeAg negative patients, as well as

fundamental insights in chronic HBV infection [106]. This may ultimately direct precision medicine approaches developed for currently licensed HBV therapies. Insights required to develop next generation inhibitors include the currently unknown aspects of HBV reverse transcription that are similar to and distinct from hepadnaviruses. Other novel targets for antiviral intervention that need to be established are the importance of restoration of the patient immune response that includes T cells, antibodies, and cytokines. Crucial areas for future research directions include the characterization of immune control associated with functional cure, the formation of neutralizing antibodies post-treatment, and the development of an immune tolerant primate model equivalent to study mechanistic studies in future HBV cure trials. Key research into the mechanisms of overlapping life cycles of HBV, HCV, HDV, and HEV may assist in identifying novel combination therapies that target all virus reservoirs [107]. A new area of emerging significance is the understanding of chronic immune profiles present in related liver disease. The international concertation and convergence of actions to establish new pipeline research collaborations is essential if current gaps are to be addressed as effectively as possible. The use of animal models, standalone or in a chimeric model, will enable a full evaluation of the novel antivirals as part of a combination of treatments and the feasibility of eradication of all the virus pools. In parallel, the development of future therapeutics, including therapeutic vaccines with novel constructs, as well as the expansion of fundamental pre-clinical and clinical research into a more comprehensive understanding than cross-reactivity induction by examining long-term tolerance and the impact the vaccine will have and the clinical implications thereof, clinical vaccine trials for full impact would be needed to provide a superior and comprehensive aim, although no vaccine policy develops [108].

The most recent development in historical attempts to find a cure for viral hepatitis lies in the development of several direct-acting antivirals which target the non-structural proteins of each genotype virus in an attempt to achieve higher viral inhibition and even reduce resistance development by a combination of different anti-HCV agents with different targets. Potential drugs to be used in combination are currently under investigation. Finally, the existence of different non-structural proteins in hepatotropic viruses or even a single virus raises new potential targets for the development of new antivirals. A combination of antiviral agents with different targets and mechanisms should be able to overcome the problem of resistance development as well as poorly effective monotherapies, thus resulting in rapid viral decay and hampering rebound [109].

Even after 15 years of research, the therapies based on direct-acting antivirals that are most effective have shown that combinations of compounds involving alternative targets result in greater viral inhibition, increasing the number of patients with undetectable viral titers. Therefore, investigators have achieved equivalent results when combining protease inhibitors with interferon plus ribavirin in HCV genotype-1 patients or when combining an NS5A inhibitor with ledipasvir. Therefore, it is becoming increasingly important to continue phase 3 and 4 clinical trials to explain the effect of these new drugs on the clinical outcomes of this group of patients [110]. It is believed that direct-acting antiviral treatment paradigms have to be adapted and new strategies have to be developed to optimally treat and achieve sustained virologic response in HCV-infected patients with current and new viral diseases. From another point of view, the target date concerning novel biotechnology discoveries is to develop drugs aimed at newly identified targets [111].

## Conclusion

Hepatitis viruses remain a major cause of liver disease worldwide, with significant implications for public health. While vaccines and antiviral therapies have made considerable strides, challenges such as diagnostic limitations, accessibility to treatment, and socioeconomic barriers continue to hinder effective management, particularly in endemic regions. Improved global strategies, including enhanced vaccination programs, early detection, and public health education, are crucial for reducing the burden of hepatitis. Additionally, ongoing research into novel antiviral therapies and a better understanding of the molecular mechanisms underlying hepatitis infections will be key to developing more effective treatments. Ultimately, a concerted effort involving healthcare systems, researchers, and policymakers is necessary to control the spread of hepatitis and its associated complications, aiming for global elimination of viral hepatitis as a public health threat.

## Acknowledgement

The authors sincerely acknowledge the support and encouragement provided by the School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab, India, for facilitating this work. The authors are also grateful to their colleagues and peers for their valuable suggestions and constructive discussions that contributed to the preparation of this review.

## Author Contribution

SR; Conceptualized the study, VK; Visualization, and FK; Prepared the manuscript draft, AS; Data Collection

## Conflict of Interest

No conflicts of interest are disclosed by the authors

## Source of Funding

There is no funding available to conduct this study.

**References**


1. J. Westin et al., "Management of hepatitis B virus infection, updated Swedish guidelines," 2020. doi: 10.1080/23744235.2019.1675903.
2. T. Ali, "Chromatography and Spectroscopic Characterization of Nano-Carrier Pharmaceuticals," Pharm. Nanotechnol., 2024, doi: 10.2174/0122117385319695240911115239.
3. C. Pan, R. Gish, I. M. Jacobson, K. Q. Hu, H. Wedemeyer, and P. Martin, "Diagnosis and Management of Hepatitis Delta Virus Infection," 2023. doi: 10.1007/s10620-023-07960-y.
4. Mukesh Kumar, Shadab Ali, and Smriti Gohri, "Microsponge Drug Delivery Systems: Advancing Methotrexate Delivery for Rheumatoid Arthritis Management," Curr. Pharm. Res., pp. 15–29, 2025, doi: 10.63785/cpr.2025.1.1.1529.
5. P. H. Almeida et al., "Update on the management and treatment of viral hepatitis," 2021. doi: 10.3748/wjg.v27.i23.3249.
6. K. Singh et al., "Recent Advances in the Synthesis of Antioxidant Derivatives: Pharmacological Insights for Neurological Disorders," Curr. Top. Med. Chem., vol. 24, no. 22, pp. 1940–1959, 2024, doi: 10.2174/0115680266305736240725052825.
7. C. Shen, X. Jiang, M. Li, and Y. Luo, "Hepatitis Virus and Hepatocellular Carcinoma: Recent Advances," 2023. doi: 10.3390/cancers15020533.
8. T. Ishimaru, K. Wada, and D. R. Smith, "A consensus for occupational health management of healthcare workers infected with human immunodeficiency virus, hepatitis B virus, and / or hepatitis C virus," J. Occup. Health, 2017, doi: 10.1539/joh.16-0275-OP.
9. M. R. Khan, D. Kumar, S. Shamim, K. Sunand, S. Sharma, and G. Rawat, "Ethnopharmacological relevance of Citrus limon (L.) Burm. f. as adjuvant therapy," Ann. Phytomedicine An Int. J., vol. 12, no. 2, pp. 169–179, 2023, doi: 10.54085/ap.2023.12.2.19.
10. D. Castaneda, A. J. Gonzalez, M. Alomari, K. Tandon, and X. B. Zervos, "From hepatitis A to E: A critical review of viral hepatitis," 2021. doi: 10.3748/wjg.v27.i16.1691.
11. Tarmeen Ali, "Nanomedicine Approaches to Overcome Barriers in Pulmonary Drug Delivery for Respiratory Diseases," Curr. Pharm. Res., pp. 30–44, 2025, doi: 10.63785/cpr.2025.1.1.3044.
12. W. J. Jeng, G. V. Papatheodoridis, and A. S. F. Lok, "Hepatitis B," 2023. doi: 10.1016/S0140-6736(22)01468-4.
13. M. Martinello, S. S. Solomon, N. A. Terrault, and G. J. Dore, "Hepatitis C," 2023. doi: 10.1016/S0140-6736(23)01320-X.
14. A. J. Stockdale, "Hepatitis D," in Comprehensive Guide to Hepatitis Advances, 2023. doi: 10.1016/B978-0-323-98368-6.00027-6.
15. Shadab Ali, Smriti Gohri, Sayad Ahad Ali, and Mukesh Kumar, "Nanotechnology for Diabetes Management: Transforming Anti-diabetic Drug Delivery Systems," Curr. Pharm. Res., pp. 45–59, 2025, doi: 10.63785/cpr.2025.1.1.4559.
16. K. Damiris, M. A. Meybodi, M. Niazi, and N. Pyrsopoulos, "Hepatitis E in immunocompromised individuals," World J. Hepatol., 2022, doi: 10.4254/wjh.v14.i3.482.
17. N. M. Araujo and C. Osiowy, "Hepatitis B Virus Genotype G: The Odd Cousin of the Family," 2022. doi: 10.3389/fmicb.2022.872766.
18. Bhanu Pratap and Pankaj Singh Jadaun, "Hydrogel Microneedles: A Breakthrough in Disease Treatment and Drug Delivery Systems," Curr. Pharm. Res., no. 204101, pp. 60–77, 2025, doi: 10.63785/cpr.2025.1.1.6077.
19. D. Q. Huang et al., "Global epidemiology of cirrhosis — aetiology, trends and predictions," 2023. doi: 10.1038/s41575-023-00759-2.
20. Shamim, S. Ali, T. Ali, H. Sharma, B. N. Kishor, and S. K. Jha, "Recent Advances in Monodisperse Gold Nanoparticle Delivery, Synthesis, and Emerging Applications in Cancer Therapy," Plasmonics, vol. 20, no. 1, 2025, doi: 10.1007/s11468-024-02732-4.
21. D. Q. Huang, A. G. Singal, Y. Kono, D. J. H. Tan, H. B. El-Serag, and R. Loomba, "Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer," Cell Metab., 2022, doi: 10.1016/j.cmet.2022.05.003.
22. Robin Singh, "Revolutionizing Antimicrobial Therapies Through Biofilm-Targeted Nanomedicine," Curr. Pharm. Res., pp. 78–97, 2025, doi: 10.63785/cpr.2025.1.1.7897.
23. F. Ghulam, N. Zakaria, M. I. Majeed, and F. Ismail, "Viral Hepatitis - The Road Traveled and the Journey Remaining," Hepatic Med. Evid. Res., 2022, doi: 10.2147/hmer.s352568.
24. A. B. Aziz et al., "Hepatitis E Virus (HEV) Synopsis: General Aspects and Focus on Bangladesh," 2023. doi: 10.3390/v15010063.
25. A. K. Jaiswal et al., "Multi-targeted therapeutic exploration of Tamarix gallica flowers for anti-ulcer activity and associated complications," J. Ayurveda Integr. Med., vol. 15, no. 4, p. 100947, 2024, doi: 10.1016/j.jaim.2024.100947.
26. Y. E. Raji, O. P. Toung, N. M. Taib, and Z. Bin Sekawi, "Hepatitis E Virus: An emerging enigmatic and underestimated pathogen," 2022. doi: 10.1016/j.sjbs.2021.09.003.
27. C. McCall, H. Wu, B. Miyani, and I. Xagoraraki, "Identification of multiple potential viral diseases in a large urban center using wastewater surveillance," Water Res., 2020, doi: 10.1016/j.watres.2020.116160.
28. Rinki Vishwas, "Peptide-Based Therapeutics in Fungal Infections: Challenges and Innovations," Curr. Pharm. Res., no. 250001, pp. 98–115, 2025, doi: 10.63785/cpr.2025.1.1.98115.
29. S. Y. Yim and J. H. Kim, "The epidemiology of hepatitis B virus infection in Korea," 2019. doi: 10.3904/kjim.2019.007.
30. Shadab Ali and Sayad Ahad Ali, "Hydrogel Nanostructures for Targeted Drug Delivery in Inflammatory Diseases: A Comprehensive Review," Curr. Pharm. Res., pp. 116–130, 2025, doi: 10.63785/cpr.2025.1.1.116130.
31. K. R. Mysore and D. H. Leung, "Hepatitis B and

C," 2018. doi: 10.1016/j.cld.2018.06.002.
32. K. Singh et al., "Deciphering the Genetic Landscape: Exploring the Relationship Between HLA-DQA1, HLA-DQB1, and HLA-DRB1 Genes in Diabetes Mellitus," Curr. Pharmacogenomics Person. Med., vol. 21, pp. 1–11, 2024, doi: 10.2174/0118756921310081240821065036.
33. Z. Miao et al., "Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection," J. Infect. Dis., 2020, doi: 10.1093/infdis/jiz633.
34. J. K. Lim, M. H. Nguyen, W. R. Kim, R. Gish, P. Perumalswami, and I. M. Jacobson, "Prevalence of Chronic Hepatitis B Virus Infection in the United States," 2020. doi: 10.14309/ajg.0000000000000651.
35. P. Kumar et al., "Fused Deposition Modeling 3D-Printed Scafolds for Bone Tissue.pdf," Appl. Biochem. Biotechnol., vol. 12, no. 22, pp. 1–11, 2024, doi: 10.54085/ap.2023.12.2.19.
36. Manisha Dev and Pallavi Chandel, "Nanostructured Lipid Carriers in Pulmonary Drug Delivery: Progress and Prospects," Curr. Pharm. Res., pp. 131–143, 2025, doi: 10.63785/cpr.2025.1.1.131143.
37. S. D'souza, K. C. K. Lau, C. S. Coffin, and T. R. Patel, "Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma," 2020. doi: 10.3748/wjg.v26.i38.5759.
38. B. Pratap, S. Shamim, and S. Ali, "Formulation and Characterisation of Herbal Ethosomal Gel of Luliconazole and Clove Oil for Modified Drug Diffusion to the Skin," Res. J. Pharm. Technol., vol. 18, no. 8, pp. 3501–3508, 2025, doi: 10.52711/0974-360X.2025.00504.
39. M. Campos-Valdez, H. C. Monroy-Ramírez, J. Armendáriz-Borunda, and L. V. Sánchez-Orozco, "Molecular mechanisms during hepatitis b infection and the effects of the virus variability," 2021. doi: 10.3390/v13061167.
40. Abhinay Tiwari, Anshu, Chirag Kumar, and Moh. Zaid, "Unravelling the Herbal Formulation of Floating Microspheres for Gut Microbiome Modulation: Curren1Abhinay Challenges and Future Prospects," Curr. Pharm. Res., pp. 144–162, 2025, doi: 10.63785/cpr.2025.1.1.144162.
41. Z. Li, D. Kong, Y. Liu, and M. Li, "Pharmacological perspectives and molecular mechanisms of coumarin derivatives against virus disease," 2022. doi: 10.1016/j.gendis.2021.03.007.
42. F. Cui et al., "Global reporting of progress towards elimination of hepatitis B and hepatitis C," Lancet Gastroenterol. Hepatol., 2023, doi: 10.1016/S2468-1253(22)00386-7.
43. A. Anand et al., "Neuroprotective Efficacy and Complementary Treatment with Medicinal Herbs: A Comprehensive Review of Recent Therapeutic Approaches in Epilepsy Management," CNS Neurol. Disord. - Drug Targets, vol. 24, no. 1, pp. 60–73, 2024, doi: 10.2174/0118715273332140240724093837.
44. M. Wang and Z. Feng, "Mechanisms of hepatocellular injury in hepatitis A," 2021. doi: 10.3390/v13050861.
45. S. et al. Singh, K., Gupta, J. K., Chanchal, D. K., Khan, S., Varma, A., Shanno, K., Kumar, S., & Shamim, "Deciphering the Genetic Landscape: Exploring the Relationship Between HLA-DQA1, HLA-DQB1, and HLA-DRB1 Genes in Diabetes Mellitus," Curr. Pharmacogenomics Person. Med., vol. 21, no. 3, pp. 1–11, 2024, doi: 10.2174/0118756921310081240821065036.
46. X. Zhao, X. Bai, and Y. Xi, "Intrauterine Infection and Mother-to-Child Transmission of Hepatitis B Virus: Route and Molecular Mechanism," 2022. doi: 10.2147/IDR.S359113.
47. S. Kausar et al., "A review: Mechanism of action of antiviral drugs," 2021. doi: 10.1177/20587384211002621.
48. S. Chawla, R. Gupta, S. K. Jha, and K. T. Jha, "Stereoisomerism in Chemistry and Drug Development: Optical, Geometrical, and Conformational Isomers," Med. Chem. (Los. Angeles)., 2025, doi: 10.2174/0115734064366389250923044201.
49. C. Herrscher, P. Roingeard, and E. Blanchard, "Hepatitis B Virus Entry into Cells," 2020. doi: 10.3390/cells9061486.
50. S. Lhomme, O. Marion, F. Abravanel, J. Izopet, and N. Kamar, "Clinical manifestations, pathogenesis and treatment of hepatitis E virus infections," 2020. doi: 10.3390/jcm9020331.
51. S. Khongviwatsathien, W. Thaweerat, T. Atthakitmongkol, W. Chotiyaputta, and T. Tanwandee, "A Comparison of Clinical Manifestations and Outcomes between Acute Sporadic Hepatitis A and Hepatitis E Infections in Thailand," Viruses, 2023, doi: 10.3390/v15091888.
52. A. et al. Kumar, J., M., T., Musayev, "Stimuli-responsive Hydrogels for Targeted Antibiotic Delivery in Bone Tissue Engineering," AAPS PharmSciTech, vol. 26, no. 217, pp. 1–23, 2025, doi: https://doi.org/10.1208/s12249-025-03218-0.
53. C. Mazzaro et al., "Hepatitis B virus-infection related cryoglobulinemic vasculitis. Clinical manifestations and the effect of antiviral therapy: A review of the literature," 2023. doi: 10.3389/fonc.2023.1095780.
54. A. T. Aslan and H. Y. Balaban, "Hepatitis E virus: Epidemiology, diagnosis, clinical manifestations, and treatment," 2020. doi: 10.3748/wjg.v26.i37.5543.
55. M. T. yan Seto, K. W. Cheung, and I. F. N. Hung, "Management of viral hepatitis A, C, D and E in pregnancy," 2020. doi: 10.1016/j.bpobgyn.2020.03.009.
56. P. Kumar et al., "Trends of Nanobiosensors in Modern Agriculture Systems," Appl. Biochem. Biotechnol., vol. 197, no. 1, pp. 667–690, 2024, doi: 10.1007/s12010-024-05039-6.
57. F. Gabrielli et al., "Treatment Options for Hepatitis A and E: A Non-Systematic Review," 2023. doi: 10.3390/v15051080.
58. S. R. Pallerla et al., "Hepatitis e virus infection: Circulation, molecular epidemiology, and impact on global health," 2020. doi: 10.3390/pathogens9100856.

59. R. J. Meshram, G. H. Kathwate, and R. N. Gacche, "Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections," 2022. doi: 10.1007/s00705-022-05375-0.
60. M. Kumar, S. Pahuja, P. Khare, and A. Kumar, "Current Challenges and Future Perspectives of Diagnosis of Hepatitis B Virus," 2023. doi: 10.3390/diagnostics13030368.
61. E. Mauriz, "Recent progress in plasmonic biosensing schemes for virus detection," 2020. doi: 10.3390/s20174745.
62. S. A. Ali, S. Ali, S. Rastogi, B. Shivhare, and M. Muztaba, "A Comprehensive Review on Advancements in Nanocarriers-Based Peptide Delivery for Cancer Therapeutics," Micro Nanosyst., vol. 17, no. 4, pp. 283–297, 2025, doi: 10.2174/0118764029358553250325040749.
63. A. Ahmed, I. A. Ali, H. Ghazal, J. Fazili, and S. Nusrat, "Mystery of hepatitis e Virus: Recent advances in its diagnosis and management," Int. J. Hepatol., 2015, doi: 10.1155/2015/872431.
64. A. Dwiartama, W. F. Nirbayati, E. A. Giri-Rachman, W. Niloperbowo, M. I. Tan, and A. Anin, "Knowledge, Attitude, and Practice towards Hepatitis B Infection Prevention and Screening among Indonesians," Int. J. Environ. Res. Public Health, 2022, doi: 10.3390/ijerph19084644.
65. J. Penner, H. Hernstadt, J. E. Burns, P. Randell, and H. Lyall, "Stop, think SCORTCH: Rethinking the traditional a TORCH' screen in an era of re-emerging syphilis," 2021. doi: 10.1136/archdischild-2020-318841.
66. O. Campollo, G. Amaya, and P. A. McCormick, "Milestones in the discovery of hepatitis C," 2022. doi: 10.3748/wjg.v28.i37.5395.
67. S. Surmiasih, H. Aprida, H. Hardono, and R. H. Putri, "Pengetahuan tentang penyakit hepatitis B dengan perilaku pemeriksaan HBsAg pada ibu hamil di Puskesmas," Wellness Heal. Mag., 2020, doi: 10.30604/well.0202.8200098.
68. P. A. Tawiah, A. Abaka-Yawson, E. S. Effah, K. Arhin-Wiredu, and K. Oppong, "Prevalence and risk factors of hepatitis B virus infection among medical laboratory science students in a Ghanaian tertiary institution," J. Heal. Res., 2022, doi: 10.1108/JHR-06-2020-0191.
69. A. G. Lim et al., "Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis," Lancet Glob. Heal., 2020, doi: 10.1016/S2214-109X(20)30003-6.
70. M. A. Daw et al., "The Epidemiology of Hepatitis D Virus in North Africa: A Systematic Review and Meta-Analysis," 2018. doi: 10.1155/2018/9312650.
71. K. M. Wylie, T. N. Wylie, R. Buller, B. Herter, M. T. Cannella, and G. A. Storch, "Detection of viruses in clinical samples by use of metagenomic sequencing and targeted sequence capture," J. Clin. Microbiol., 2018, doi: 10.1128/JCM.01123-18.
72. E. I. Reipold et al., "Values, preferences and current hepatitis B and C testing practices in low- and middle-income countries: Results of a survey of end users and implementers," BMC Infect. Dis., 2017, doi: 10.1186/s12879-017-2769-y.
73. P. J. Easterbrook, T. Roberts, A. Sands, and R. Peeling, "Diagnosis of viral hepatitis," 2017. doi: 10.1097/COH.0000000000000370.
74. L. Y. J. Ahovègbé et al., "Therapeutic potentials of Vachellia nilotica (L.) extracts in Hepatitis C infection: A review," 2021. doi: 10.1016/j.sciaf.2021.e00918.
75. J. Young et al., "Evaluation of a Program to Improve Linkage to and Retention in Care Among Refugees with Hepatitis B Virus Infection — Three U.S. Cities, 2006–2018," MMWR. Morb. Mortal. Wkly. Rep., 2020, doi: 10.15585/mmwr.mm6921a2.
76. M. Cornberg, J. Mischke, A. R. Kraft, and H. Wedemeyer, "Immunological scars after cure of hepatitis C virus infection: Long-HepC?," 2023. doi: 10.1016/j.coi.2023.102324.
77. M. R. Brunetto et al., "EASL Clinical Practice Guidelines on hepatitis delta virus," J. Hepatol., 2023, doi: 10.1016/j.jhep.2023.05.001.
78. R. C. Langan and A. J. Goodbred, "Hepatitis A," Am. Fam. Physician, 2021, doi: 10.12968/pnur.2005.16.2.17500.
79. N. A. Terrault, M. T. Levy, K. W. Cheung, and G. Jourdain, "Viral hepatitis and pregnancy," 2021. doi: 10.1038/s41575-020-00361-w.
80. D. Oliveira, F. Pereira, M. do R. Martins, R. Castro, L. Cordeiro, and I. Fronteira, "A systematic review of the maternal and neonatal complications in hepatitis B infection," 2020. doi: 10.1016/j.jcv.2020.104680.
81. M. Michael Pou and J. Dube, "Seroprevalence and associated risk factors for Hepatitis B Virus infections among apparently healthy pregnant mothers attending Anc in Rubkona primary health care center in Rubkona County, Unity State, South Sudan," Arch. Hepat. Res., 2021, doi: 10.17352/ahr.000029.
82. N. Urganci, D. Kalyoncu, and S. G. Gulec, "Hepatitis a in children: Evaluation of atypical manifestations," Paediatr. Indones. Indones., 2020, doi: 10.14238/pi60.5.2020.239-43.
83. P. Ripellino et al., "Neurologic complications of acute hepatitis E virus infection," Neurol. Neuroimmunol. NeuroInflammation, 2020, doi: 10.1212/NXI.0000000000000643.
84. R. Brenig and C. Bernsmeier, "Liver Cirrhosis," Praxis (Bern. 1994)., 2023, doi: 10.53730/ijhs.v6ns1.6109.
85. M. Adanusa et al., "Sero-prevalence of Hepatitis B and C at a Primary Healthcare centre in Ghana," AfricArXiv, 2023, doi: 10.21428/3b2160cd.fded76d8.
86. I. M. Sayed, "Dual Infection of Hepatitis A Virus and Hepatitis E Virus— What Is Known?," 2023. doi: 10.3390/v15020298. T. T. Lao, "Hepatitis B – chronic carrier status and pregnancy outcomes: An obstetric perspective," 2020. doi: 10.1016/j.bpobgyn.2020.03.006.
87. E. Keles et al., "Clinical characteristics of acute

liver failure associated with hepatitis A infection in children in Mogadishu, Somalia: a hospital-based retrospective study," BMC Infect. Dis., 2021, doi: 10.1186/s12879-021-06594-7.
88. M. L. Ferraz et al., "Brazilian Society of Hepatology and Brazilian Society of Infectious Diseases Guidelines for the Diagnosis and Treatment of Hepatitis B," 2020. doi: 10.1016/j.bjid.2020.07.012.
89. L. Lapointe-Shaw et al., "Peri-complication diagnosis of hepatitis C infection: Risk factors and trends over time," Liver Int., 2021, doi: 10.1111/liv.14670.
90. S. C. Rogan and R. H. Beigi, "Management of Viral Complications of Pregnancy: Pharmacotherapy to Reduce Vertical Transmission," 2021. doi: 10.1016/j.ogc.2020.12.001.
91. A. Guzman-Holst et al., "Burden of disease and associated complications of hepatitis a in children and adults in Mexico: A retrospective database study," PLoS One, 2022, doi: 10.1371/journal.pone.0268469.
92. B. Sundstrom, K. B. Cartmell, A. A. White, H. Well, J. Y. Pierce, and H. M. Brandt, "Correcting HPV vaccination misinformation online: Evaluating the HPV vaccination NOW social media campaign," Vaccines, 2021, doi: 10.3390/vaccines9040352.
93. C. J. Williams et al., "The Initial Relationship Between the United States Department of Health and Human Services' Digital COVID-19 Public Education Campaign and Vaccine Uptake: Campaign Effectiveness Evaluation," J. Med. Internet Res., 2023, doi: 10.2196/43873.
94. Z. Niu and G. Scarciotti, "Ranking the effectiveness of non-pharmaceutical interventions to counter COVID-19 in UK universities with vaccinated population," Sci. Rep., 2022, doi: 10.1038/s41598-022-16532-5.
95. C. A. Adjei, S. E. Stutterheim, F. Naab, and R. A. C. Ruiter, "Barriers to chronic Hepatitis B treatment and care in Ghana: A qualitative study with people with Hepatitis B and healthcare providers," PLoS One, 2019, doi: 10.1371/journal.pone.0225830.
96. N. Patel et al., "Acute Hepatitis of Unknown Origin in Pediatric Age Group: Recent Outbreaks and Approach to Management," 2023. doi: 10.3390/jcm12010009.
97. P. O. Klingmann et al., "Editorial.," J. Musculoskelet. Pain, 2014.
98. E. De Martin, J. M. Michot, O. Rosmorduc, C. Guettier, and D. Samuel, "Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors," 2020. doi: 10.1016/j.jhepr.2020.100170.
99. M. A. Corcorran, K. Thornton, B. Struminger, P. Easterbrook, and J. D. Scott, "Training the healthcare workforce: the global experience with telementorship for hepatitis B and hepatitis C," BMC Health Serv. Res., 2023, doi: 10.1186/s12913-023-09849-y.
100. J. Neuberger, "Long-term Care of the Adult Liver Transplant Recipient," 2022. doi: 10.1016/j.jceh.2022.03.012.
101. H. Zheng, N. Walsh, O. Lesi, and F. Cui, "New progress towards elimination of mother-to-child transmission of hepatitis B virus in China," Hepatol. Int., 2022, doi: 10.1007/s12072-022-10400-0.
102. W. R. Treem et al., "Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis," Drug Saf., 2021, doi: 10.1007/s40264-020-01014-2.
103. B. Nicoletta et al., "Management of psoriatic patients in biologic treatment associated with infectious comorbidities," Postep. Dermatologii i Alergol., 2020, doi: 10.5114/ada.2020.96155.
104. D. Morgnanesi, E. J. Heinrichs, A. R. Mele, S. Wilkinson, S. Zhou, and J. L. Kulp, "A computational chemistry perspective on the current status and future direction of hepatitis B antiviral drug discovery," 2015. doi: 10.1016/j.antiviral.2015.10.014.
105. C. Relton et al., "2nd TwiCs symposium summary," Trials, 2017.
106. M. J. Heuschkel, T. F. Baumert, and E. R. Verrier, "Cell culture models for the study of hepatitis d virus entry and infection," 2021. doi: 10.3390/v13081532.
107. S. Chowdhary et al., "Recent Updates on Viral Oncogenesis: Available Preventive and Therapeutic Entities," 2023. doi: 10.1021/acs.molpharmaceut.2c01080.
108. H. Maruyama and S. Shiina, "Pathogenesis of hepatitis C virus-related hepatocellular carcinoma: Evidence from recent studies," 2021. doi: 10.21037/JPHE-2021-04.
109. M. L. Yu et al., "2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations," J. Formos. Med. Assoc., 2020, doi: 10.1016/j.jfma.2020.04.002.
110. D. Praditya, L. Kirchhoff, J. Brüning, H. Rachmawati, J. Steinmann, and E. Steinmann, "Anti-infective properties of the golden spice curcumin," 2019. doi: 10.3389/fmicb.2019.00912.